ICU Medical, Inc. - 10-Q Summary (Q1 2004)
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2004. ICU Medical, Inc. is a Delaware corporation engaged in the development, manufacturing, and marketing of disposable medical devices, primarily needleless connectors (CLAVE) and custom intravenous (I.V.) systems, designed to prevent the spread of infectious diseases. The company operates principally in one business segment.
Key Financial Metrics
| Metric (in thousands) | Q1 2004 | Q1 2003 |
|---|---|---|
| Total Revenue | $22,233 | $30,776 |
| Net Sales | $21,270 | $28,736 |
| Gross Profit | $12,420 | $17,752 |
| Gross Margin (of Net Sales) | 54% | 55% |
| Operating Income | $6,314 | $11,194 |
| Net Income | $4,140 | $7,070 |
| Diluted EPS | $0.28 | $0.46 |
| Cash from Operations | $12,850 | $4,646 |
| Cash & Liquid Investments | $85,748 | $73,137 (Dec 31, 2003) |
| Working Capital | $108,194 | $102,932 (Dec 31, 2003) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 28% ($8.5 million) compared to Q1 2003. Approximately $5.7 million of this decrease is attributed to non-recurring items in Q1 2003, specifically a $4.0 million deferral of CLAVE shipments from late 2002 and a one-time $1.7 million license fee. Excluding these items, the underlying revenue decline was approximately 9.5%.
- Net Income Drop: Net income fell 41% to $4.14 million, driven by the revenue decline and a slight compression in gross margins.
- Customer Concentration: Sales to Hospira, Inc. (formerly Abbott's Hospital Products Division) accounted for 60% of total net revenues in Q1 2004, down from 68% in Q1 2003. Net sales to Hospira decreased 36% year-over-year, largely due to inventory reductions by the customer and the absence of the deferred shipments mentioned above.
- Product Mix Shift: While standalone CLAVE sales decreased, sales of custom I.V. systems increased 25% to $6.1 million. International sales grew 70% year-over-year.
- Inventory Build: Inventories increased 74% to $5.9 million as the company began building finished goods inventory in anticipation of higher second-half demand.
Guidance, Outlook, and Risks
- Outlook: Management expects CLAVE unit and dollar sales volume to increase for the full year 2004 compared to 2003. Significant growth is anticipated in the SetSource custom I.V. systems program with Hospira. Gross margins are expected to see a modest increase in 2004 but are not expected to reach the historical benchmark of 57%.
- Capital Expenditures: Estimated at approximately $6.0 million for the full year 2004, primarily for molds, equipment, and software to maintain capacity and support targeted growth.
- Key Risks:
- Customer Dependence: The company relies heavily on Hospira for revenue. An adverse change in this relationship or Hospira's market position could materially harm operations.
- Competition: Competitive pressure may force continued price reductions on CLAVE products, though volume increases have historically offset this.
- Regulatory: Future product launches depend on FDA approvals (e.g., new connector and diabetes market product).
- Legal: Ongoing patent infringement litigation against B. Braun Medical, Inc. regarding the UltraSite connector.
Investor Verification Checklist
- Verify the sustainability of the 60% revenue concentration with Hospira and the impact of the recent contract amendments extending terms to 2014.
- Monitor the execution of the strategy to shift revenue mix from standalone CLAVE connectors to higher-value custom I.V. systems.
- Assess the impact of the 74% inventory increase on future working capital requirements and potential obsolescence risks.
- Track the status of the patent litigation against B. Braun and potential royalty revenue from the SafeLine revenue share agreement.
- Confirm the timeline for FDA approval and market launch of the new connector and diabetes market products.